一文总结!降低脂蛋白a的药物有哪些?哪些可以应用于临床?
一项纳入了7项随机对照研究一共2337名患者的荟萃分析的结果提示,同安慰剂比较,依折麦布单药(10mg/日)能够降低原发性高胆固醇血症患者Lp(a)水平7.06%(95% CI:-11.95~-2.18;p=0.005)[14]。
虽然这种程度的减少幅度临床意义较少,但是提示我们临床上针对Lp(a)水平升高的患者可以考虑使用依折麦布治疗。
米泊美生(Mipomersen)是一种载脂蛋白B(apoB)的反义寡核苷酸抗体,其能够降低Lp(a)水平约25%,同时能够降低心血管事件的发生。
但是由于该药物的临床副反应,因此仅仅批准用于纯合子家族性高胆固醇血症患者,并不适用于常规的降脂治疗[25,26]。
Inclisiran是针对PCSK9的一种小干扰RNA(siRNA),其能够抑制肝脏细胞PCSK9信使RNA的翻译,进而降低PCSK-9介导的LDLR的降解并且增加LDLR的重吸收[30]。
I期临床研究提示该药物临床安全性较好,同时能够降低PCSK9水平84%,LDL水平60%。II期临床研究的ORION-1研究提示该药物能够以剂量依赖的方式减少Lp(a)水平14%~25%[31]。可以看出,在降低Lp(a)水平方面,Inclisiran有类似其他PCSK9抑制剂的降低幅度。目前本药物的III期临床研究正在进行中。
[1]Jang AY, Han SH, Sohn IS, Oh PC, Koh KK. Lipoprotein(a) and Cardiovascular Diseases - Revisited. Circ J. 2020 May 25;84(6):867-874.
[2]Jacobson TA. Lipoprotein(a), cardiovascular disease, and contemporary management. Mayo Clin Proc. 2013 Nov;88(11):1294-311.
[3]Youssef A, Clark JR, Koschinsky ML, Boffa MB. Lipoprotein(a): Expanding our knowledge of aortic valve narrowing. Trends Cardiovasc Med. 2020 Jun 7:S1050-1738(20)30080-3.
[4]Tsimikas S. Potential Causality and Emerging Medical Therapies for Lipoprotein(a) and Its Associated Oxidized Phospholipids in Calcific Aortic Valve Stenosis. Circ Res. 2019 Feb;124(3):405-415.
[5]Khan TZ, Bornstein SR, Barbir M. Lipoprotein(a): the underutilized risk factor for cardiovascular disease. Glob Cardiol Sci Pract. 2019 Sep 20;2019(2):e201911.
[6]Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111-188.
[7]Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Jun 18;139(25):e1082-e1143. doi: 10.1161/CIR.0000000000000625. Epub 2018 Nov 10. Erratum in: Circulation. 2019 Jun 18;139(25):e1182-e1186. PMID: 30586774; PMCID: PMC7403606.
[8]赵水平. 《中国成人血脂异常防治指南(2016年修订版)》要点与解读[J]. 中华心血管病杂志, 2016, 44(10):827-829.
[9]Enkhmaa B, Berglund L. Statins and Lp(a): The plot thickens. Atherosclerosis. 2019 Oct;289:173-175. doi: 10.1016/j.atherosclerosis.2019.07.021. Epub 2019 Aug 6. PMID: 31443913; PMCID: PMC7098730.
[10]Banach M, Penson PE. Statins and Lp(a): do not make perfect the enemy of excellent. Eur Heart J. 2020 Jan 1;41(1):190-191. doi: 10.1093/eurheartj/ehz775. PMID: 31893479.
[11]Wang X, Li J, Ju J, Fan Y, Xu H. Effect of different types and dosages of statins on plasma lipoprotein(a) levels: A network meta-analysis. Pharmacol Res. 2021 Jan;163:105275. doi: 10.1016/j.phrs.2020.105275. Epub 2020 Nov 7. PMID: 33166736.
[12]Yahya R, Berk K, Verhoeven A, Bos S, van der Zee L, Touw J, Erhart G, Kronenberg F, Timman R, Sijbrands E, Roeters van Lennep J, Mulder M. Statin treatment increases lipoprotein(a) levels in subjects with low molecular weight apolipoprotein(a) phenotype. Atherosclerosis. 2019 Oct;289:201-205. doi: 10.1016/j.atherosclerosis.2019.07.001. Epub 2019 Jul 3. PMID: 31327478.
[13]Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statins and increases in Lp(a): an inconvenient truth that needs attention. Eur Heart J. 2020 Jan 1;41(1):192-193. doi: 10.1093/eurheartj/ehz776. PMID: 31893480.
[14]Awad K, Mikhailidis DP, Katsiki N, Muntner P, Banach M; Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group. Effect of Ezetimibe Monotherapy on Plasma Lipoprotein(a) Concentrations in Patients with Primary Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Drugs. 2018 Mar;78(4):453-462. doi: 10.1007/s40265-018-0870-1. PMID: 29396832.
[15]Gencer B, Mach F. Potential of Lipoprotein(a)-Lowering Strategies in Treating Coronary Artery Disease. Drugs. 2020 Feb;80(3):229-239. doi: 10.1007/s40265-019-01243-5. PMID: 31916186.
[16]Stulnig TM, Morozzi C, Reindl-Schwaighofer R, Stefanutti C. Looking at Lp(a) and Related Cardiovascular Risk: from Scientific Evidence and Clinical Practice. Curr Atheroscler Rep. 2019 Jul 27;21(10):37. doi: 10.1007/s11883-019-0803-9. PMID: 31350625.
[17]Julius U, Fischer S. Nicotinic acid as a lipid-modifying drug--a review. Atheroscler Suppl. 2013 Jan;14(1):7-13. doi: 10.1016/j.atherosclerosissup.2012.10.036. PMID: 23357134.
[18]Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Nicotinic Acid and new-onset diabetes. Horm Metab Res. 2015 Jun;47(7):544-5. doi: 10.1055/s-0034-1387703. Epub 2014 Aug 19. PMID: 25137408.
[19]Taskinen MR, Puolakka J, Pyörälä T, Luotola H, Bjäörn M, Kääriänen J, Lahdenperä S, Ehnholm C. Hormone replacement therapy lowers plasma Lp(a) concentrations. Comparison of cyclic transdermal and continuous estrogen-progestin regimens. Arterioscler Thromb Vasc Biol. 1996 Oct;16(10):1215-21. doi: 10.1161/01.atv.16.10.1215. PMID: 8857916.
[20]Shlipak MG, Simon JA, Vittinghoff E, Lin F, Barrett-Connor E, Knopp RH, Levy RI, Hulley SB. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA. 2000 Apr 12;283(14):1845-52. doi: 10.1001/jama.283.14.1845. PMID: 10770146.
[21]Ragusa R, Basta G, Neglia D, De Caterina R, Del Turco S, Caselli C. PCSK9 and atherosclerosis: Looking beyond LDL regulation. Eur J Clin Invest. 2021 Apr;51(4):e13459. doi: 10.1111/eci.13459. Epub 2020 Dec 3. PMID: 33236356.
[22]O'Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, Im K, Lira Pineda A, Wasserman SM, Češka R, Ezhov MV, Jukema JW, Jensen HK, Tokgözoğlu SL, Mach F, Huber K, Sever PS, Keech AC, Pedersen TR, Sabatine MS. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation. 2019 Mar 19;139(12):1483-1492. doi: 10.1161/CIRCULATIONAHA.118.037184. PMID: 30586750.
[23]Ruscica M, Greco MF, Ferri N, Corsini A. Lipoprotein(a) and PCSK9 inhibition: clinical evidence. Eur Heart J Suppl. 2020 Nov 18;22(Suppl L):L53-L56. doi: 10.1093/eurheartj/suaa135. PMID: 33239979; PMCID: PMC7673619.
[24]Julius U, Tselmin S, Schatz U, Fischer S, Bornstein SR. Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors. Clin Res Cardiol Suppl. 2019 Apr;14(Suppl 1):45-50. doi: 10.1007/s11789-019-00099-z. PMID: 30838555.
[25]Gencer B, Mach F. Potential of Lipoprotein(a)-Lowering Strategies in Treating Coronary Artery Disease. Drugs. 2020 Feb;80(3):229-239. doi: 10.1007/s40265-019-01243-5. PMID: 31916186.
[26]Fogacci F, Ferri N, Toth PP, Ruscica M, Corsini A, Cicero AFG. Efficacy and Safety of Mipomersen: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Drugs. 2019 May;79(7):751-766. doi: 10.1007/s40265-019-01114-z. PMID: 30989634.
[27]Wu MF, Xu KZ, Guo YG, Yu J, Wu Y, Lin LM. Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current Understanding and Future Perspectives. Cardiovasc Drugs Ther. 2019 Dec;33(6):739-748. doi: 10.1007/s10557-019-06906-9. PMID: 31655942.
[28]Duell PB, Jialal I. Modern Management of Familial Hypercholesterolemia. Metab Syndr Relat Disord. 2016 Dec;14(10):463-467. doi: 10.1089/met.2016.29011.due. Epub 2016 Oct 31. PMID: 27797643.
[29]Crooke ST, Baker BF, Crooke RM, Liang XH. Antisense technology: an overview and prospectus. Nat Rev Drug Discov. 2021 Mar 24. doi: 10.1038/s41573-021-00162-z. Epub ahead of print. PMID: 33762737.
[30]Macchi C, Sirtori CR, Corsini A, Santos RD, Watts GF, Ruscica M. A new dawn for managing dyslipidemias: The era of rna-based therapies. Pharmacol Res. 2019 Dec;150:104413. doi: 10.1016/j.phrs.2019.104413. Epub 2019 Aug 23. PMID: 31449975.
[31]Ray KK, Stoekenbroek RM, Kallend D, Leiter LA, Landmesser U, Wright RS, Wijngaard P, Kastelein JJP. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1. Circulation. 2018 Sep 25;138(13):1304-1316. doi: 10.1161/CIRCULATIONAHA.118.034710. PMID: 29735484.
[32]Marcovina SM, Viney NJ, Hughes SG, Xia S, Witztum JL, Tsimikas S. Temporal variability in lipoprotein(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)Rx and IONIS-APO(a)-LRx antisense oligonucleotide clinical trials. J Clin Lipidol. 2018 Jan-Feb;12(1):122-129.e2. doi: 10.1016/j.jacl.2017.10.024. Epub 2017 Nov 2. PMID: 29174389.
[33]Fernández-Ruiz I. AKCEA-APO(a)-LRx lowers Lp(a) levels in patients. Nat Rev Cardiol. 2020 Mar;17(3):132. doi: 10.1038/s41569-020-0336-5. PMID: 31949304.
[34]Mäkinen P, Ruotsalainen AK, Ylä-Herttuala S. Nucleic Acid-Based Therapies for Atherosclerosis. Curr Atheroscler Rep. 2020 Feb 7;22(2):10. doi: 10.1007/s11883-020-0826-2. PMID: 32034521; PMCID: PMC7007442.
[35]Filippatos TD, Kei A, Elisaf MS. Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias? Diseases. 2017 Sep 29;5(4):21. doi: 10.3390/diseases5040021. PMID: 28961179; PMCID: PMC5750532.
[36]Ferri N, Corsini A, Sirtori CR, Ruscica M. Present therapeutic role of cholesteryl ester transfer protein inhibitors. Pharmacol Res. 2018 Feb;128:29-41. doi: 10.1016/j.phrs.2017.12.028. Epub 2017 Dec 26. PMID: 29287689.
[37]Scott LJ. Tocilizumab: A Review in Rheumatoid Arthritis. Drugs. 2017 Nov;77(17):1865-1879. doi: 10.1007/s40265-017-0829-7. Erratum in: Drugs. 2017 Dec 19;: PMID: 29094311; PMCID: PMC5736769.
[38]García-Gómez C, Martín-Martínez MA, Castañeda S, Sanchez-Alonso F, Uriarte-Ecenarro M, González-Juanatey C, Romera-Baures M, Santos-Rey J, Pinto-Tasende JA, Quesada-Masachs E, Tornero-Molina J, Martínez-González O, Cobo-Ibáñez T, Chamizo-Carmona E, Manrique-Arija S, Fábregas-Canales D, Díaz-González F, Llorca J, González-Gay MA; CARMA Project Collaborative Group. Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: Results from the CARdiovascular in rheuMAtology study project. J Clin Lipidol. 2017 May-Jun;11(3):749-756.e3. doi: 10.1016/j.jacl.2017.02.018. Epub 2017 Mar 16. PMID: 28476652.
[39]Shetty A, Hanson R, Korsten P, Shawagfeh M, Arami S, Volkov S, Vila O, Swedler W, Shunaigat AN, Smadi S, Sawaqed R, Perkins D, Shahrara S, Sweiss NJ. Tocilizumab in the treatment of rheumatoid arthritis and beyond. Drug Des Devel Ther. 2014 Mar 28;8:349-64. doi: 10.2147/DDDT.S41437. PMID: 24729685; PMCID: PMC3974690.
[40]Anstensrud AK, Woxholt S, Sharma K, Broch K, Bendz B, Aakhus S, Ueland T, Amundsen BH, Damås JK, Hopp E, Kleveland O, Stensæth KH, Opdahl A, Kløw NE, Seljeflot I, Andersen GØ, Wiseth R, Aukrust P, Gullestad L. Rationale for the ASSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation myocardial infarction (STEMI). Open Heart. 2019 Oct 15;6(2):e001108. doi: 10.1136/openhrt-2019-001108. PMID: 31673391; PMCID: PMC6803013.
[41]Que X, Hung MY, Yeang C, Gonen A, Prohaska TA, Sun X, Diehl C, Määttä A, Gaddis DE, Bowden K, Pattison J, MacDonald JG, Ylä-Herttuala S, Mellon PL, Hedrick CC, Ley K, Miller YI, Glass CK, Peterson KL, Binder CJ, Tsimikas S, Witztum JL. Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice. Nature. 2018 Jun;558(7709):301-306. doi: 10.1038/s41586-018-0198-8. Epub 2018 Jun 6. Erratum in: Nature. 2018 Sep;561(7724):E43. PMID: 29875409; PMCID: PMC6033669.
[42]Cherepanova OA, Srikakulapu P, Greene ES, Chaklader M, Haskins RM, McCanna ME, Bandyopadhyay S, Ban B, Leitinger N, McNamara CA, Owens GK. Novel Autoimmune IgM Antibody Attenuates Atherosclerosis in IgM Deficient Low-Fat Diet-Fed, but Not Western Diet-Fed Apoe-/- Mice. Arterioscler Thromb Vasc Biol. 2020 Jan;40(1):206-219. doi: 10.1161/ATVBAHA.119.312771. Epub 2019 Oct 24. PMID: 31645128; PMCID: PMC7006879.
[43]Shoemaker TJ, Kono T, Mariash CN, Evans-Molina C. Thyroid hormone analogues for the treatment of metabolic disorders: new potential for unmet clinical needs? Endocr Pract. 2012 Nov-Dec;18(6):954-64. doi: 10.4158/EP12086.RA. PMID: 22784847; PMCID: PMC3745011.
[44]Anagnostis P, Karras S, Lambrinoudaki I, Stevenson JC, Goulis DG. Lipoprotein(a) in postmenopausal women: assessment of cardiovascular risk and therapeutic options. Int J Clin Pract. 2016 Dec;70(12):967-977. doi: 10.1111/ijcp.12903. PMID: 28032426.
[45]Kelly MJ, Pietranico-Cole S, Larigan JD, Haynes NE, Reynolds CH, Scott N, Vermeulen J, Dvorozniak M, Conde-Knape K, Huang KS, So SS, Thakkar K, Qian Y, Banner B, Mennona F, Danzi S, Klein I, Taub R, Tilley J. Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β agonist in clinical trials for the treatment of dyslipidemia. J Med Chem. 2014 May 22;57(10):3912-23. doi: 10.1021/jm4019299. Epub 2014 Apr 8. PMID: 24712661.
[46]Fiorucci S, Distrutti E. Chenodeoxycholic Acid: An Update on Its Therapeutic Applications. Handb Exp Pharmacol. 2019;256:265-282. doi: 10.1007/164_2019_226. PMID: 31267167.
[47]Ghosh Laskar M, Eriksson M, Rudling M, Angelin B. Treatment with the natural FXR agonist chenodeoxycholic acid reduces clearance of plasma LDL whilst decreasing circulating PCSK9, lipoprotein(a) and apolipoprotein C-III. J Intern Med. 2017 Jun;281(6):575-585. doi: 10.1111/joim.12594. Epub 2017 Feb 1. PMID: 28145001.
本文首发:医学界心血管频道
本文作者:Myo Yun Jung,南京
责任编辑:袁雪晴 章丽
赞 (0)